tumor mutational burden
Real-World Data Analysis Confirms Pan-Cancer Predictiveness of Foundation Medicine TMB Caller
Premium
The company worked with clinical investigators to analyze outcomes data across more than 8,000 treated individuals, reconfirming the validity of its FDA-approved TMB indication.
Association for Molecular Pathology Releases New Tumor Mutational Burden Testing Recommendations
The joint consensus guideline, authored by AMP, ASCO, CAP, and SITC, seeks to establish evidence-based standards for validation and reporting of TMB tests in the clinic.
CAP Releases Testing Guidelines for Immunotherapy Biomarkers in NSCLC
The guidelines focus on how pathologists use approved assays or LDTs, how the results are reported, and which patients should be tested.
A comparison for 144 solid tumor samples showed a "high degree of alignment" with FoundationOne CDx and better calling of CNAs than Illumina's TSO 500.
Epic Sciences Raises $24M, Expands Commercial Infrastructure for Breast Cancer Liquid Biopsy Test
The firm is growing its sales, product marketing, and customer service teams for its multiomic metastatic breast cancer liquid biopsy test, DefineMBC.